According to the company, once a prescriber was placed on the so-called "global exclude" list, they stayed on. One Endo executive testified that the company stopped marketing its opioids to health care providers if their prescribing practices raised safety concerns. The court also found some of the documents contradicted sworn testimony provided by Endo witnesses. The company faces a wave of opioid-related lawsuits and previously settled other cases with counties in Ohio in 2019 and with the state of Oklahoma last year.Īs commonly occurs in litigation, Endo fought in Tennessee to avoid sharing internal documents, communications and memos that describe its business dealings.īut in September 2018, Moody issued an order requiring Endo to divulge detailed information about prescribers it worked with, company efforts to stop abuse of Opana ER, and other opioid-related matters.Īccording to Moody's order, Endo's team made at least a dozen false statements during court proceedings and withheld hundreds of thousands of documents, many of them directly relevant to the case. That misuse also contributed to outbreaks of infectious diseases including HIV and Hepatitis C. Local governments suing the company have demanded roughly $2.4 billion in damages.Įndo ended sales of Opana ER in 2017 after the Food & Drug Administration found it was often abused by people who crushed, dissolved and injected the medication. Almost all our crime is driven by drugs," he told NPR. "It's overdose deaths, it's people losing their jobs, losing their dignity. It has really ripped at the fabric of our community," said Barry Staubus, district attorney in Sullivan County Tennessee. They claim Endo's opioid medication Opana ER was marketed aggressively in the state without proper safeguards, contributing to high rates of addiction and death.
Endo pharma things to look for series#
Stranch's legal team filed a series of complaints with the court about Endo's conduct in the case, which led to the judge's order.Ī controversial opioid, a devastating epidemicĪt issue is a lawsuit filed in 2017 by county prosecutors and other local government officials in eastern Tennessee. " lawyers crossed the line and worked with the company to subvert the court's orders and then made false statements to the court about it," he said.
Endo pharma things to look for trial#
In a statement emailed to NPR the company said it will appeal the judgement.īut Gerard Stranch, one of the attorneys suing the drugmaker on behalf of local governments in Tennessee, said Endo and its lawyers "conspired to hide the truth" over a period of years as the fact-finding phase of the trial proceeded. Moody in a judgment issued on April 6.Įndo denies wrongdoing.
"It appears to the court that Endo and its attorneys, after delaying trial, have resorted to trying to improperly corrupt the record," wrote Chancellor E.G. The judge presiding over the civil trial also concluded the drugmaker and its attorneys made at least a dozen false statements during the pretrial fact-finding process. After the deal, Endo will have about 4,000 employees.A state judge in Tennessee ruled the drug company Endo Pharmaceuticals is liable for harm caused by their opioid drug, Opana ER.Ī state court in Tennessee has punished Endo Pharmaceuticals for improperly withholding a vast trove of documents relating to the sale and marketing of its opioid medication Opana ER. The boards of both companies approved the sale, and Endo said the deal should close late in the third quarter. The company makes the Lidoderm pain patch, Fortesta testosterone gel, and the pain drugs Opana and Opana ER, among other products. In November, Endo acquired Penwest Pharmaceuticals for $144 million.Įndo had $1.72 billion in revenue in 2010. It’s the latest in a string of acquisitions for Endo, which paid $1.2 billion for Qualitest Pharmaceuticals, a maker of pain treatments and generic drugs, in December. It also sells urinary incontinence and vaginal prolapse products for women’s health, and markets laser therapies for enlarged prostate.Įndo, of Chadds Ford, Pa., said the deal is part of its transition from a drugmaker to a health care company. Almost half its revenue comes from sales of men’s health products and drugs for urinary incontinence and impotence.
The Minnetonka, Minn., company reported $542.3 million in sales in 2010. Endo will also assume $312 million in American Medical’s debt.Īmerican Medical Systems makes devices and therapies for pelvic health, urology, and gynecology. for about $2.6 billion.Įndo is offering $30 a share - a premium of 34 percent to the most recent closing price of American Medical Systems shares. said Monday it is buying urology and pelvic health company American Medical Systems Inc. NEW YORK (AP) - Chadds Ford-based Endo Pharmaceuticals Holdings Inc.
0 kommentar(er)
